{"id":"W2046487711","doi":"10.1097/mib.0b013e318281f2b7","title":"52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants","year":2013,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"UCB Pharma; Genentech; Atlantic Healthcare; Relypsa; Astellas Pharma; Eisai; ActoGeniX; Shire; Bristol-Myers Squibb; Eli Lilly and Company; Orexigen Therapeutics; Biogen; Celgene; Therakos; Novo Nordisk; Teva Pharmaceutical Industries; Gilead Sciences; Takeda Oncology; Tillotts Pharma; Amgen; Pfizer; Ironwood Pharmaceuticals, Incorporated","keywords":"Ulcerative colitis; Adalimumab; Medicine; Gastroenterology; Internal medicine; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002727705,0.0006405965,0.001563487,0.0002451787,0.0003392046,0.0005596579,0.0003260902,0.000549236,0.001260368],"category_scores_gemma":[0.002214096,0.0002928009,0.001112714,0.0002574511,0.0002171528,0.0004741977,0.0003251031,0.0009779615,0.0003804452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003494814,"about_ca_system_score_gemma":0.0003532331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003599195,"about_ca_topic_score_gemma":0.000648089,"domain_scores_codex":[0.9993038,0.0003188027,0.00007294249,0.0001426288,0.00007125292,0.00009054702],"domain_scores_gemma":[0.9985001,0.0003983117,0.0005103816,0.0001654344,0.0000744131,0.0003513808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7095505,0.01058313,0.1128364,0.0008149995,0.002847771,0.000303477,0.0003540803,0.001886571,0.01567175,0.0000543356,0.001600053,0.1434969],"study_design_scores_gemma":[0.1219174,0.2855083,0.5803437,0.0001761897,0.002040413,0.000594342,0.000103187,0.002957362,0.003197008,0.0001579766,0.002930276,0.00007376329],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970554,0.001731038,0.0001655028,0.00007143881,0.00002097229,0.0001574684,0.0002155388,0.00002221214,0.0005603825],"genre_scores_gemma":[0.9986357,0.0002420888,0.0001866316,0.0001411281,0.00003013811,0.0001345886,0.0003884485,0.000003408154,0.0002378783],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002727705,"threshold_uncertainty_score":0.01442564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006517874569077723,"score_gpt":0.2184965100514673,"score_spread":0.2119786354823895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}